NDASUBCUTANEOUSSOLUTION
Approved
Dec 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
SIGNIFOR (pasireotide) by Recordati is somatostatin receptor agonists [moa]. Approved for cushing's disease, acromegaly. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIGNIFOR (pasireotide) is a somatostatin receptor agonist administered subcutaneously for treatment of neuroendocrine and hormone-secreting tumors. It binds multiple somatostatin receptors to inhibit hormone secretion and tumor growth across a broad range of indications including Cushing's disease, acromegaly, carcinoid tumors, and gastroenteropancreatic neuroendocrine tumors. The drug's multi-receptor activity enables efficacy across diverse endocrine pathologies.
$0.001BPart D
LOE Approaching7mo to LOEWith patent expiry in late 2026 and minimal current spending, SIGNIFOR faces imminent generic competition and likely downsizing of commercial infrastructure.
Mechanism of Action
Somatostatin Receptor Agonists
Pharmacologic Class:
Somatostatin Analog
Indications (2)
Clinical Trials (20)
Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
Started Dec 2025
40 enrolled
PharmacokineticsSafety
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Started Dec 2024
28 enrolled
Desmoplastic Small Round Cell TumorSynovial Sarcoma
A Study of Pasireotide in People With Prolactinoma
Started Feb 2024
10 enrolled
Prolactin-Producing Pituitary Tumor
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Started Jan 2024
93 enrolled
Post-Bariatric Hypoglycemia
Pasireotide in Hyperinsulinemic Hypoglycemia
Started Apr 2017
0Congenital HyperinsulinismInsulinomaHyperinsulinism
Worked on SIGNIFOR at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.